Wells Fargo

The investment bank said that it thinks 2018 will be a good year for clinical sequencing and that overall demand for high-throughput sequencing remains high. 

Wells Fargo downgraded Cepheid from Outperform to Market Perform, citing the firm's "credibility and visibility" following a revised 2017 outlook.

In a report issued today, analysts said the company failed to provide "meaningfully improved visibility on broader reimbursement and revenue progression."

The investment bank noted stabilization in Myriad's BRCA1/2 testing franchise, the firm's new management, and its new products. 

The upgrade follows four consecutive quarters of above-industry-average revenue growth, driven by the biopharma end market, and the addition of a new CEO.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

CNBC reports that there are thousands of genetic tests available for consumers to chose between.

In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.